Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/99254
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gravia, Aikaterini | - |
dc.contributor.author | Chondrou, Vasiliki | - |
dc.contributor.author | Sgourou, Argyro | - |
dc.contributor.author | Papantoni, Ioanna | - |
dc.contributor.author | Borg, Joseph J. | - |
dc.contributor.author | Katsila, Theodora | - |
dc.contributor.author | Papachatzopoulou, Adamantia | - |
dc.contributor.author | Patrinos, George P. | - |
dc.date.accessioned | 2022-07-13T08:02:15Z | - |
dc.date.available | 2022-07-13T08:02:15Z | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | Gravia, A., Chondrou, V., Sgourou, A., Papantoni, I., Borg, J., Katsila, T., ... & Patrinos, G. P. (2014). Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients. Pharmacogenomics, 15(10), 1355-1364. | en_GB |
dc.identifier.uri | https://www.um.edu.mt/library/oar/handle/123456789/99254 | - |
dc.description.abstract | Individual genetic composition is an important cause of variations in the response and tolerance to drug treatment. Pharmacogenomics is a modern discipline aiming to delineate individual genomic profiles and drug response. To date, there are several medical disciplines where pharmacogenomics is readily applicable, while in others its usefulness is yet to be demonstrated. Recent experimental evidence suggests that besides genomic variation within the human β-globin gene cluster, other variants in modifier genes residing outside the human β-globin gene cluster are significantly associated with response to hydroxyurea treatment in β-type hemoglobinopathies patients, deducted from the increase in fetal hemoglobin levels. This article aims to provide an update and to discuss future challenges on the application of pharmacogenomics for β-type hemoglobinopathies therapeutics in relation to the current pharmacological treatment modalities for those disorders. | en_GB |
dc.language.iso | en | en_GB |
dc.publisher | Future Medicine Ltd. | en_GB |
dc.rights | info:eu-repo/semantics/restrictedAccess | en_GB |
dc.subject | Thalassemia -- Diagnosis | en_GB |
dc.subject | Pharmacogenomics -- Research | en_GB |
dc.subject | Sickle cell anemia -- Genetic aspects | en_GB |
dc.subject | Single nucleotide polymorphisms | en_GB |
dc.title | Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients | en_GB |
dc.type | article | en_GB |
dc.rights.holder | The copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder | en_GB |
dc.description.reviewed | peer-reviewed | en_GB |
dc.identifier.doi | 10.2217/PGS.14.101 | - |
dc.publication.title | Pharmacogenomics | en_GB |
Appears in Collections: | Scholarly Works - FacHScABS |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Individualizing_fetal_hemoglobin_augmenting_therapy_for_β_type_hemoglobinopathies_patients.pdf Restricted Access | 717.79 kB | Adobe PDF | View/Open Request a copy |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.